Related references
Note: Only part of the references are listed.Somatostatin analog octreotide LAR (R) in gastro-entero-pancreatic tumors
Kjell Oberg
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Medical management of pancreatic neuroendocrine tumors
Thierry Delaunoit et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors
Sirianong Namwongprom et al.
ANNALS OF NUCLEAR MEDICINE (2008)
Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
K. Oberg et al.
ANNALS OF ONCOLOGY (2008)
Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors
Rudolf Arnold et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs
D. Campana et al.
ENDOCRINE-RELATED CANCER (2008)
Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours
Simona Grozinsky-Glasberg et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors
Irvin M. Modlin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Gastroenteropancreatic neuroendocrine tumours
Irvin M. Modlin et al.
LANCET ONCOLOGY (2008)
Neuroendocrine tumors of the gastro-entero-pancreatic system
Sara Massironi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Circulating markers for endocrine tumours of the gastroenteropancreatic tract
Joy E. S. Ardill
ANNALS OF CLINICAL BIOCHEMISTRY (2008)
Consensus guidelines for the management of patients with liver metastases from digestive (neuro) endocrine tumors: Foregut, midgut, hindgut, and unknown primary
Thomas Steinmueller et al.
NEUROENDOCRINOLOGY (2008)
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy
Marco Volante et al.
MODERN PATHOLOGY (2007)
Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue
Sylvain Manfredi et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2007)
TNM staging of midgut and hindgut (neuro) endocrine tumors:: a consensus proposal including a grading system
G. Rindi et al.
VIRCHOWS ARCHIV (2007)
Chromogranin A: Is it a useful marker of neuroendocrine tumors?
Davide Campana et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Nuclear imaging of neuroendocrine tumours
Anders Sundin et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?
N. Fazio et al.
ANNALS OF ONCOLOGY (2007)
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study
Maria Chiara Zatelli et al.
ENDOCRINE-RELATED CANCER (2007)
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma
G. Butturini et al.
ENDOCRINE-RELATED CANCER (2006)
Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors - A phase III study
Emilio Bajetta et al.
CANCER (2006)
TNM staging of foregut (neuro)endocrine tumors:: a consensus proposal including a grading system
G. Rindi et al.
VIRCHOWS ARCHIV (2006)
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma
F Panzuto et al.
ANNALS OF ONCOLOGY (2006)
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours
JK Ramage et al.
GUT (2005)
Enteroendocrine tumors other than carcinoid: A review of clinically significant advances
RRP Warner
GASTROENTEROLOGY (2005)
Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids
M Peracchi et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Treatment of ECL cell carcinoids with octreotide LAR
V Fykse et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2004)
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
K Öberg et al.
ANNALS OF ONCOLOGY (2004)
Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours
D Nehar et al.
CLINICAL ENDOCRINOLOGY (2004)
The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut
JES Ardill et al.
ENDOCRINE-RELATED CANCER (2003)
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors -: The International Lanreotide and Interferon Alfa Study Group
S Faiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role
M Cimitan et al.
ANNALS OF ONCOLOGY (2003)
Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours
L Kölby et al.
BRITISH JOURNAL OF SURGERY (2003)
Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1
M Peracchi et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003)
Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma
H Shojamanesh et al.
CANCER (2002)
Share Paper
